Ten-year follow-up on LASIK for high myopia reported

Article

Results of 10-year follow-up of patients with high myopia who underwent LASIK indicate that the procedure is safe and effective over the long term.

Results of 10-year follow-up of patients with high myopia who underwent LASIK indicate that the procedure is safe and effective over the long term, said Juan J. Perez-Santonja, MD, Alicante Institute of Ophthalmology, Miguel Hernandez University, Alicante, Spain. In his study, 40% of eyes avoided use of spectacles, best spectacle-corrected visual acuity (BSCVA) improved 1 line, and complications were infrequent.

However, predictability was low, there was a high chance of re-treatment, and refraction was never stable over the 10-year period. Dr. Perez-Santonja said. Thus, the data do not support LASIK as a first-choice procedure for patients with myopia of more than -10 D, he added.

Dr. Perez-Santonja reported the outcomes of surgery in 196 eyes (118 patients) with a spherical equivalent of more than -10 D who had myopic LASIK between April 1994 and December 1995. They had follow-up visits at 3 months, 1 year, 3 years, 5 years, and 10 years; 54 eyes (27%) were re-treated.

Significant improvement in distance uncorrected and best-corrected visual acuity was seen between 3 months and 1 year in three categories: re-treated eyes, eyes with no re-treatment, and all eyes. Vision remained stable up to at least 5 years. The percentage of eyes with uncorrected visual acuity 20/40 or better was 50% at 1 year and 51%%at 5 years, but it declined to 39% at 10 years.

Mean BSCVA improved 1 line after surgery. Fifteen eyes (7.6%) lost 2 or more lines of visual acuity in 10 years, although the loss was attributable to complications from LASIK rather than from high myopia in only 3 eyes, Dr. Perez-Santonja said.

The spherical equivalent improved postoperatively for all time points; however, there was also a continuous decrease over time, especially in eyes that were not re-treated. Myopic regression was 1 D in the first year, 0.5 D in the second year, 0.18 D per year between the second and fifth year, and 0.15 D per year between the fifth and the tenth year.

"If we add all of these results together, we have 2.5 D of regression over time after LASIK," Dr. Perez-Santonja said. The regression correlated with the magnitude of achieved correction.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.